CXCR4拮抗剂
| 英文名 | AMD-070 | CAS号 | 558447-26-0 |
| 试剂别名 |
(S)-N1-((1H-Benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine;AMD-070;1,4-Butanediamine, N1-(1H-benzimidazol-2-ylmethyl)-N1-[(8S)-5,6,7,8- tetrahydro-8-quinolinyl]-;AMD 070 N-(1H-benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]- (9CI);mavorixafor;N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine;AMD 070;N'-(1H-Benzimidazol-2-ylmethyl)-N'-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine
|
分子式 | C21H27N5 |
| 产品编号 | APEA3173 | 分子量 | 349.48 |
| MDL号 |
| 产品名称： | CXCR4拮抗剂 |
| 英文名称： | AMD-070 |
| 英文别名： | (S)-N1-((1H-Benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine;AMD-070;1,4-Butanediamine, N1-(1H-benzimidazol-2-ylmethyl)-N1-[(8S)-5,6,7,8- tetrahydro-8-quinolinyl]-;AMD 070 N-(1H-benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]- (9CI);mavorixafor;N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine;AMD 070;N'-(1H-Benzimidazol-2-ylmethyl)-N'-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine |
| 中文别名： | N'-(1H-苯并咪唑-2-甲基)-N'-((S)-5,6,7,8-四氢喹啉-8-基)丁烷-1,4-二胺;N''-(1H-苯并咪唑-2-甲基)-N''-((S)-5,6,7,8-四氢喹啉-8-基)丁烷-1,4-二胺;N-(1H-苯并咪唑-2-甲基)-N-((S)-5,6,7,8-四氢喹啉-8-基)丁烷-1,4-二胺;N1-(1H-苯并咪唑-2-甲基)-N1-[(8S)-5,6,7,8-四氢-8-喹啉]-1,4-二氨基丁烷;N`-(1H-苯并咪唑-2-甲基)-N`-((S)-5,6,7,8-四氢喹啉-8-基)丁烷-1,4-二胺 |
| CAS No.： | 558447-26-0 |
| 分子式： | C21H27N5 |
| 分子量： | 349.48 |
| 危险品级别： | |
| HS符号： | |
| 危害声明： |
